STOCK TITAN
  1. Home
  2. Financials
  3. QTZM

Quantumzyme Financials

QTZM
Source SEC Filings (10-K/10-Q) Data as of Apr 30, 2026 Currency USD FYE July

This page shows Quantumzyme (QTZM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI QTZM FY2025

Recent filings show a liability-heavy shell as cash and total assets nearly disappeared while obligations kept rising.

In FY2025, total assets were just $184 against total liabilities of $491K, showing an obligation structure far larger than the asset base. The imbalance worsened from the prior year, when assets were $10K and liabilities were $353K; with current assets equal to cash, the 0.0004 current ratio implies almost no short-term liquidity buffer.

The share count rose from 34.8M to 39.0M over the same span. Yet cash fell from $5K to $184, so a larger equity base did not coincide with balance-sheet repair. Current assets matching cash also suggests little working capital beyond the smallest liquid resource.

Some figures from recent filings were inconsistent and were omitted from this summary.

Generated by Rhea from SEC filings [ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score pending refresh

We are recalculating Quantumzyme's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$0

Quantumzyme generated $0 in revenue in fiscal year 2025.

EBITDA
N/A
Net Income
N/A
EPS (Diluted)
$-0.01
YoY+0.0%

Quantumzyme earned $-0.01 per diluted share (EPS) in fiscal year 2025. This represents an increase of 0.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow
N/A
Cash & Debt
$184
YoY-96.4%

Quantumzyme held $184 in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share
N/A
Shares Outstanding
39M
YoY+12.0%

Quantumzyme had 39M shares outstanding in fiscal year 2025. This represents an increase of 12.0% from the prior year.

Margins & Returns

Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
Return on Equity
N/A

Capital Allocation

R&D Spending
N/A
Share Buybacks
N/A
Capital Expenditures
N/A

QTZM Income Statement

Metric Q3'26 Q2'26 Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24
Revenue $0 $0 $0 N/A $0 $0 $0 N/A
Cost of Revenue N/A N/A N/A N/A N/A N/A N/A N/A
Gross Profit N/A N/A N/A N/A N/A N/A N/A N/A
R&D Expenses N/A N/A N/A N/A N/A N/A N/A N/A
SG&A Expenses N/A N/A N/A N/A N/A $3K+111.5% $2K N/A
Operating Income N/A N/A N/A N/A N/A -$25K+59.7% -$61K N/A
Interest Expense N/A N/A N/A N/A N/A $5K+14.9% $5K N/A
Income Tax $0 $0 $0 N/A $0 $0 $0 N/A
Net Income N/A N/A N/A N/A N/A -$30K+54.5% -$66K N/A
EPS (Diluted) $0.00+100.0% $-0.12 $0.00 N/A $0.00 $0.00 $0.00 N/A

QTZM Balance Sheet

Metric Q3'26 Q2'26 Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24
Total Assets $590.0% $59-67.9% $184-68.5% $5840.0% $584 N/A N/A $10K
Current Assets $590.0% $59-67.9% $184-68.5% $5840.0% $584 N/A N/A $10K
Cash & Equivalents $590.0% $59-67.9% $184-68.5% $5840.0% $584-66.7% $2K-65.4% $5K $0
Inventory N/A N/A N/A N/A N/A N/A N/A N/A
Accounts Receivable N/A N/A N/A N/A N/A N/A N/A N/A
Goodwill N/A N/A N/A N/A N/A N/A N/A N/A
Total Liabilities $443K+6.0% $418K-14.7% $491K+11.2% $441K+9.5% $403K N/A N/A $293K
Current Liabilities $443K+6.0% $418K-14.7% $491K+11.2% $441K+9.5% $403K N/A N/A $293K
Long-Term Debt N/A N/A N/A N/A N/A N/A N/A N/A
Total Equity -$443K-6.0% -$418K+14.7% -$491K-11.3% -$441K-9.5% -$403K-7.9% -$373K-8.7% -$343K-21.2% -$283K
Retained Earnings -$10.0M-0.2% -$10.0M-76.1% -$5.7M-0.9% -$5.6M-0.7% -$5.6M N/A N/A -$5.4M

QTZM Cash Flow Statement

Metric Q3'26 Q2'26 Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24
Operating Cash Flow N/A N/A N/A N/A N/A -$15K+58.6% -$35K-160.6% -$13K
Capital Expenditures N/A N/A N/A N/A N/A N/A N/A N/A
Free Cash Flow N/A N/A N/A N/A N/A N/A N/A N/A
Investing Cash Flow N/A N/A N/A N/A N/A N/A N/A N/A
Financing Cash Flow N/A N/A N/A N/A N/A $11K-72.1% $40K+198.3% $13K
Dividends Paid N/A N/A N/A N/A N/A N/A N/A N/A
Share Buybacks N/A N/A N/A N/A N/A N/A N/A N/A

QTZM Financial Ratios

Metric Q3'26 Q2'26 Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24
Gross Margin N/A N/A N/A N/A N/A N/A N/A N/A
Operating Margin N/A N/A N/A N/A N/A N/A N/A N/A
Net Margin N/A N/A N/A N/A N/A N/A N/A N/A
Return on Equity N/A N/A N/A N/A N/A N/A N/A N/A
Return on Assets N/A N/A N/A N/A N/A N/A N/A N/A
Current Ratio 0.000.0 0.000.0 0.000.0 0.000.0 0.00 N/A N/A 0.03
Debt-to-Equity -1.000.0 -1.000.0 -1.000.0 -1.000.0 -1.00 N/A N/A -1.04
FCF Margin N/A N/A N/A N/A N/A N/A N/A N/A

Note: Shareholder equity is negative (-$491K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Frequently Asked Questions

Quantumzyme (QTZM) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Quantumzyme (QTZM) reported diluted earnings per share of $-0.01 for fiscal year 2025. This represents a 0.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Quantumzyme (QTZM) had $184 in total assets as of fiscal year 2025, including both current and long-term assets.

Quantumzyme (QTZM) had 39M shares outstanding as of fiscal year 2025.

Quantumzyme (QTZM) had a current ratio of 0.00 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

Quantumzyme (QTZM) had a debt-to-equity ratio of -1.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Quantumzyme (QTZM) has negative shareholder equity of -$491K as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Back to top